Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 2;19(15):9490.
doi: 10.3390/ijerph19159490.

The Long Goodbye: Finally Moving on from the Relative Potency Approach to a Mixtures Approach for Polycyclic Aromatic Hydrocarbons (PAHs)

Affiliations

The Long Goodbye: Finally Moving on from the Relative Potency Approach to a Mixtures Approach for Polycyclic Aromatic Hydrocarbons (PAHs)

Lynne T Haber et al. Int J Environ Res Public Health. .

Abstract

For the past several decades, a relative potency approach has been used to estimate the human health risks from exposure to polycyclic aromatic hydrocarbon (PAH) mixtures. Risk estimates are derived using potency equivalence factors (PEFs; also called relative potency factors [RPFs]), based on the ratio of selected PAHs to benzo[a]pyrene (BaP), expressed qualitatively by orders of magnitude. To quantify PEFs for 18 selected carcinogenic PAHs, a systematic approach with a priori and dose response criteria was developed, building on draft work by the US EPA in 2010 and its review by US EPA Science Advisory Board (SAB) in 2011. An exhaustive search for carcinogenicity studies that included both _target PAHs and BaP with environmentally relevant exposure routes found only 48 animal bioassay datasets (mostly pre-1992 based on skin painting). Only eight datasets provided adequate low-response data, and of these only four datasets were appropriate for modeling to estimate PEFs; only benzo[b]fluoranthene and cyclopenta[c,d]pyrene had a PEF that could be quantified. Thus, current knowledge of PAH carcinogenicity is insufficient to support quantitative PEFs for PAH mixtures. This highlights the long-acknowledged need for an interdisciplinary approach to estimate risks from PAH mixtures. Use of alternative and short-term toxicity testing methods, improved mixture characterization, understanding the fate and bioavailability of PAH mixtures, and understanding exposure route-related differences in carcinogenicity are discussed as ways to improve the understanding of the risks of PAHs.

Keywords: PAHs; PEF; RPF; mixtures; potency.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Conceptual Model of Approach to Data Gathering and Analysis.

Similar articles

Cited by

References

    1. IARC, Working Group on the Evaluation of Carcinogenic Risk to Humans . IARC Monographs on the Evaluation of Carcinogenesisenic Risks to Humans. Volume 92 Int Agency Res Cancer; Lyon, France: 2010. Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures. - PMC - PubMed
    1. Kalberlah F., Frijus-Plessen N., Hassauer M. Toxicological criteria for the risk assessment of polyaromatic hydrocarbons (PAH) in existing chemicals. Part 1: The use of equivalency factors. Altlasten-Spektrum. 1995;5:231–237. As cited in WHO/IPCS 1998. (In Germany)
    1. WHO/IPCS, (World Health Organization, International Programme on Chemical Safety) Selected Non-Heterocyclic Polycyclic Aromatic Hydrocarbons. WHO; Geneva, Switzerland: 1998. Environ Health Criteria 202.
    1. US EPA . Peer Consultation Workshop on Approaches to Polycyclic Aromatic Hydrocarbon (PAH) Health Assessment. U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment; Washington, DC, USA: 2002. EPA/635/R-02/005.
    1. Schoeny R., Muller P., Mumford J. Risk Assessment for Human Health Protection-Applications to Environmental Mixtures. Pollut. Risk Assess Mgmt. 1998;205:51–83.

Publication types

Substances

Grants and funding

This research was funded by Health Canada’s Standing Offer, 4600001175 for contract work conducted in 2016, 2018 and 2019.
  NODES
admin 1
INTERN 1
twitter 2